Sermorelin,
clearly compared.
Understand how peptides differ, read the evidence, and compare what provider prices actually include.
Research linked. Price terms explained.
Same conversation.
Different peptides.
Half-life describes clearance. It does not establish how long benefits last or an appropriate injection schedule.
Explore the full comparisonStart with the difference that matters.
Clear comparisons of mechanism, half-life and regulatory status.
GHRH analogs vs ghrelin mimetics
Four of these five reach the pituitary one way. The fifth does not.
Read comparisonCJC-1295 vs sermorelin
Same class, and the CJC-1295 you are quoted may be either of two molecules.
Read comparisonSermorelin vs ipamorelin
Different receptors, very different clearance, and only one ever approved.
Read comparisonTesamorelin vs ipamorelin
Sold as a pair by some sellers, and their half-lives sit at opposite ends.
Read comparisonLook beyond the headline price.
Read the medication, payment terms and questions to ask before choosing a provider.
System Labs
Partner$109first month · introductory offer
Then $219 per month after the first month.
Published offer · Sermorelin injection — monthly 9 mg plan.
Read review
Embody
Partner$49first month · introductory offer
Then $99 per month after first month.
Published offer · Sermorelin Injection.
Read review
Strut Health
Partner$119per month
Published offer · Sermorelin Injectable.
Read review
CoreAge Rx
PartnerFrom $99per month
Published offer · Sermorelin.
Read reviewPartners appear first. This is a directory preview, not a quality or price ranking. How we are paid.
Explore all five peptides.
Compare the recorded evidence while keeping formulations and approval contexts distinct.
Compare the evidence, one attribute at a time.
| Attribute | Sermorelin | Tesamorelin | Ipamorelin | CJC-1295 (no DAC) | CJC-1295 + DAC |
|---|---|---|---|---|---|
| Mechanism | GHRH analog 1 | GHRH analog 3 | ghrelin mimetic 6 | GHRH analog 3 | GHRH analog 3 |
| Half-life | 10–20 min 1 | 8 min 4EGRIFTA WR label: “11 minutes in healthy subjects after single dose subcutaneous administration of the 1.28 mg of EGRIFTA WR” EGRIFTA WR label, revised 03/2025 | ~2 hours 7 | not reported in humans 3 | 5.8–8.1 days 9 |
| Cortisol / prolactin | not recorded | not recorded | no cortisol or prolactin rise in conscious swine 8In humans: “comparatively minimal activation of other pituitary–adrenal axes in available human studies” Dominikowski et al. 2026 | not recorded | not recorded |
| FDA status | withdrawn 2 | approved (Egrifta SV) 4 | no approval for these uses 3 | not approved 3 | not approved 3 |
| Reported use | 200–300 µg once daily, typically before bedtime 3 | 2 mg once daily 3 | 200–300 µg, 2 or 3 injections a day, often with CJC-1295 (no DAC) 3 | 100–200 µg per injection, 1–2 times daily, often with ipamorelin 3 | 1–2 mg/week, in 1–2 injections 3 |
Choose a peptide for its evidence and limits.
SermorelinHalf-life10–20 min 1
TesamorelinHalf-life8 min 4
- Mechanism
- GHRH analog 3
- Half-life
- 8 min 4EGRIFTA WR label: “11 minutes in healthy subjects after single dose subcutaneous administration of the 1.28 mg of EGRIFTA WR” EGRIFTA WR label, revised 03/2025
- Cortisol / prolactin
- not recorded
- FDA status
- approved (Egrifta SV) 4
- Reported use
- 2 mg once daily 3
IpamorelinHalf-life~2 hours 7
- Mechanism
- ghrelin mimetic 6
- Half-life
- ~2 hours 7
- Cortisol / prolactin
- no cortisol or prolactin rise in conscious swine 8In humans: “comparatively minimal activation of other pituitary–adrenal axes in available human studies” Dominikowski et al. 2026
- FDA status
- no approval for these uses 3
- Reported use
- 200–300 µg, 2 or 3 injections a day, often with CJC-1295 (no DAC) 3
CJC-1295 (no DAC)Half-lifenot reported in humans 3
The reported-use row is what people describe doing online, collected in a peer-reviewed review that labels its own table “anthropological/behavioural data, not clinical recommendations”. It is not prescribing information, and it is not what any seller here charges for.
Explore the half-life chart and its sources
- TESTesamorelin8 min
- SERSermorelin10–20 min
- IPAIpamorelin~2 hours
- CJC-DCJC-1295 + DAC5.8–8.1 days
Values are preserved as reported, including ranges. No human half-life is reported for CJC-1295 without DAC.
Put the details to work.
Check a quote, compare its cost and understand what the numbers mean.
Peptide half-life calculator
Explore estimated amounts remaining over time, with the measured ranges and evidence limits kept visible.
Explore half-lifeProvider quote checklist
Keep track of twelve questions about supply, pharmacy, fees and cancellation before accepting a quote.
Prepare your questionsSermorelin plan cost calculator
Add your quoted charges to compare the first payment, renewals and full cost across whole billing cycles.
Calculate plan costUnderstand the treatment before the offer.
Start with the evidence, its limits, and the practical questions worth taking to a clinician.
Explore the research libraryFollow the evidence.
Original study and regulatory documents behind the comparison.
9 documents, in the order the figures above use them. The date on each is the one printed on the document.
- Esposito P, Barbero L, Caccia P, Caliceti P, D'Antonio M, Piquet G, Veronese FM. PEGylation of growth hormone-releasing hormone (GRF) analogues.Document date: 2003-09-26. PMID 14499707, doi:10.1016/s0169-409x(03)00109-1.
- Food and Drug Administration, Department of Health and Human Services. Determination That GEREF (Sermorelin Acetate) Injection, 0.5 Milligrams Base/Vial and 1.0 Milligrams Base/Vial, and GEREF (Sermorelin Acetate) Injection, 0.05 Milligrams Base/Amp, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness.Document date: published 2013-03-04, signed 2013-02-26. 78 FR 14095, FR Doc. 2013-04827, Docket No. FDA-2012-P-1071.
- Dominikowski A, Rękoś Z, Olejarz M, Szczepanek-Parulska E, Domin R, Ruchała M. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.Document date: 2026-06-18. PMID 42395176, PMC13322892, doi:10.3389/fendo.2026.1822475.
- Theratechnologies Inc., prescribing information approved by the Food and Drug Administration. EGRIFTA SV (tesamorelin) for injection, for subcutaneous use — full prescribing information.Document date: label face date: Revised 03/2024; label version published 2026-07-31. SPL set id 3d783378-b02d-4f19-99dd-0fc91a042224, Initial U.S. Approval 2010.
- Theratechnologies Inc., prescribing information approved by the Food and Drug Administration. EGRIFTA WR (tesamorelin) for injection, for subcutaneous use — full prescribing information.Document date: label face date: Revised 03/2025; label version published 2026-08-03. SPL set id 839334d3-8c1d-4c26-9036-2ab524a6ea75, Initial U.S. Approval 2010.
- Venkova K, Mann W, Nelson R, Greenwood-Van Meerveld B. Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus.Document date: 2009-06. PMID 19289567, doi:10.1124/jpet.108.149211.
- Gobburu JV, Agersø H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.Document date: 1999-09. PMID 10496658, doi:10.1023/a:1018955126402.
- Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue.Document date: 1998-11. PMID 9849822, doi:10.1530/eje.0.1390552.
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.Document date: 2006-03. PMID 16352683, doi:10.1210/jc.2005-1536.